Figure 1

Time courses of ADMA, SDMA, CRP, IL-6, S100B, MCP-1, TIMP-1 and MMP-9 after ischemic stroke. Data are presented as mean and standard error. Between group comparisons of marker levels in patients and controls: *P <0.05: significant differences in TIMP-1 levels at 3 d. %P <0.05: significant differences in IL-6 levels at different time points. $P <0.05: significant differences in SDMA levels at 6 h. #P <0.05: significant differences in ADMA levels at different time points. &P <0.05: significant differences in S100B levels at different time points. Within-group comparisons of marker levels between baseline (6 h) and follow-up time points: significant differences (P <0.05) were detected for TIMP-1 (6 h vs. 3 d, 6 h vs. 7 d), MMP-9 (6 h vs. 12 h, 6 h vs. 24 h, 6 h vs. 3 d, 6 h vs. 7 d), IL-6 (6 h vs. 3 d, 6 h vs. 7 d), CRP (6 h vs. 12 h, 6 h vs. 24 h), SDMA (6 h vs. 12 h, 6 h vs. 24 h, 6 h vs. 3 d), ADMA (6 h vs. 12 h, 6 h vs. 24 h, 6 h vs. 3 d, 6 h vs. 7 d) and S100B (6 h vs. 24 h, 6 h vs. 3 d). ADMA, asymmetric dimethylarginine; CRP, C-reactive protein; IL-6, interleukin-6; MCP-1, monocyte chemotactic protein-1; MMP-9, matrix metalloproteinase-9; SDMA, symmetric dimethylarginine; TIMP-1, tissue inhibitor of matrix metalloproteinase-1.